Nicholas Fussell, DPM
Foot & Ankle Surgery · Nashville, TNNPI 1619399540
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 255 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 40 manufacturers reported payments, led by Smith+Nephew at 25.3% of the total.
Across 255 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$1K
- Organogenesis Inc.$1K
- Aroa Biosurgery Incorporated$540
- Stryker$248
- Kerecis Limited$216
- Medtronic$188
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,545100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 90 | $1,406 |
| Organogenesis Inc. | 45 | $1,151 |
| Aroa Biosurgery Incorporated | 12 | $540 |
| Stryker | 10 | $248 |
| Kerecis Limited | 6 | $216 |
| Medtronic | 6 | $188 |
| Amgen(2 entities) | 8 | $143 |
| Melinta Therapeutics, LLC | 7 | $124 |
| AbbVie | 7 | $123 |
| Paratek Pharmaceuticals, Inc. | 7 | $122 |
| Acera Surgical, Inc. | 6 | $103 |
| Polynovo North America LLC | 3 | $97 |
| DJO, LLC | 3 | $73 |
| Orthofix Medical, Inc. | 5 | $71 |
| Averitas Pharma Inc. | 2 | $69 |
| GRT US Holding, Inc. | 3 | $59 |
| Paragon 28, Inc. | 3 | $58 |
| Osteocentric Technologies, Inc. | 1 | $57 |
| Avita Medical Americas, LLC | 1 | $56 |
| Treace Medical Concepts, Inc. | 3 | $53 |
| Zimmer Biomet | 1 | $49 |
| Acumed LLC | 1 | $46 |
| Osiris Therapeutics Inc. | 2 | $41 |
| Lifenet Health | 1 | $39 |
| Reapplix Inc. | 1 | $39 |
| Nevro Corp. | 2 | $37 |
| Integra Lifesciences Corporation | 2 | $33 |
| Solventum Corporation | 2 | $33 |
| Johnson & Johnson | 1 | $31 |
| Convatec Inc. | 1 | $30 |
| Bsn Medical Inc | 1 | $29 |
| Merck | 2 | $27 |
| Triad Life Sciences Inc. | 2 | $26 |
| Bioventus LLC | 1 | $23 |
| Zyla Life Sciences, Inc. | 2 | $23 |
| Mimedx Group, Inc. | 1 | $22 |
| Polarityte, Inc. | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$5,545 in reported general payments places this provider in the 60th percentile of 145 foot & ankle surgery providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 12 | $5,970 |
| Clotrimazole | 35 | $1,328 |
| Clindamycin Hcl | 32 | $410 |
| Clobetasol Propionate | 13 | $337 |
| Mupirocin | 49 | $297 |
| Gabapentin | 30 | $242 |
| Methylprednisolone | 34 | $232 |
| Terbinafine Hcl | 24 | $215 |
| Doxycycline Monohydrate | 17 | $167 |
| Levofloxacin | 25 | $164 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $154 |
| Ciprofloxacin Hcl | 15 | $115 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $39 |
| Cephalexin | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $1,406 | $5,97012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 145 foot & ankle surgery providers in Tennessee.
Other foot & ankle surgery in Nashville
- William CornNashville$52K
- Sheela ChockalingamNashville$15K
- Christopher DreikornNashville$13K
- Andrew PierreNashville$10K
- Bethany GallagherNashville$8K
- Jeffrey WillersNashville$7K
- Reva BorkNashville$7K
- Timothy BushNashville$7K
- Jeffrey HerringNashville$5K
- Sebastien DemoinyMorristown$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.